Akèy › Kansè poumon selil ti › Massachusetts › Boston
Etid klinik pou Kansè poumon selil ti nan Boston, MA
21 etid pou Kansè poumon selil ti ap chèche patisipan nan sit nan ak bò kote Boston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
Ap rekriteFaz 2
- Dana-Farber Cancer Institute /ID# 277732, Boston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1
- Dana Farber Cancer Institute, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Ap rekriteFaz 1/2
- Tufts Medical Center, Boston
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
Ap rekriteFaz 3
- Dana-Farber Cancer Institute /ID# 279690, Boston
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Ap rekriteFaz 1/2
- Dana Farber Cancer Institute ( Site 1105), Boston
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Ap rekriteFaz 1/2
- Avenzo Therapeutics Recruiting Site, Boston
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Ap rekriteFaz 1/2
- Dana Farber Cancer Institute, Boston
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
Ap rekriteFaz 2
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Massachusetts General Hospital Cancer Center, Boston
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Ap rekriteFaz 3
- Dana-Farber Cancer Institute, Boston
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Ap rekriteFaz 1
- Beth Israel Deaconess Medical Center, Boston
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
Ap rekriteFaz 2
- Dana Farber Cancer Institute, Boston
A Study of LY4175408 in Participants With Advanced Cancer
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Ap rekriteFaz 2
- Tufts Medical Center, Boston
Biology of Young Lung Cancer Study: The YOUNG LUNG Study
Ap rekriteEtid obsèvasyon
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Brigham and Women's Hospital, Boston
- ak 1 plis
DNA Analysis of Blood and Tissue from Patients with Lung Cancer
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Massachusetts General Hospital, Boston
- Harvard School of Public Health, Boston
Etid Kansè poumon selil ti nan lòt vil
- Houston, TX26 etid
- Arlington, VA23 etid
- New York City, NY21 etid
- Nashville, TN20 etid
- Los Angeles, CA20 etid
- Orlando, FL15 etid
- Dallas, TX13 etid
- St. Louis, MO13 etid
- Cleveland, OH13 etid
- Detroit, MI12 etid
- Chicago, IL12 etid
- Washington, DC12 etid
Lòt etid nan Boston
- Kansè nan tete111 etid
- Kansè Poumon ki pa ti selil90 etid
- Kansè (tout kalite)86 etid
- Kansè kolorektal63 etid
- Kansè Metastatik63 etid
- Kansè poumon62 etid
- Kansè ovè61 etid
- Kansè pwostat59 etid
- Depresyon52 etid
- Kansè Endomèt50 etid
- Ensifizyans kadyak44 etid
- Leksemi mieloïd egi44 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.